arrow
A

Andrew L. Kung

Memorial Sloan Kettering Cancer Center
H指数:105
被引数:4.8万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Prior therapy defines mutation profiles in childhood cancer at relapse

既往治疗定义了儿童癌症复发时的突变谱

Nature
IF48.5
2026-07-220
OAAI
IL7-Receptor–Targeted CAR T-Cell Therapy for T-Cell Acute Lymphoblastic Leukemia

IL7-受体靶向CAR T细胞疗法治疗T细胞急性淋巴细胞白血病

2026-07-150
OAAI
Single-cell protein activity analysis reveals aberrant myogenesis and IGF2-PI3K pathway dependencies in MYOD1-mutant rhabdomyosarcoma

单细胞蛋白质活性分析揭示了MYOD1突变型横纹肌肉瘤中异常的肌发生以及IGF2-PI3K通路的依赖性。

2026-02-270
OA
Enabling whole genome sequencing analysis from FFPE specimens in clinical oncology

实现从FFPE标本在临床肿瘤学中进行全基因组测序分析

2025-11-270
OAAI
Epigenetic targeting of PGBD5-dependent DNA damage in SMARCB1-deficient sarcomas

表观遗传靶向SMARCB1缺乏性肉瘤中PGBD5依赖性的DNA损伤

2025-10-152
OA
Author Correction: Feasibility of whole genome and transcriptome profiling in pediatric and young adult cancers

作者更正:全基因组与转录组谱分析在儿童及年轻成人癌症中的可行性

2025-09-030
OAAI
Author Correction: Clonal evolution during metastatic spread in high-risk neuroblastoma

作者更正:高危神经母细胞瘤转移扩散过程中的克隆进化

2025-08-050
PRE
Lessons learned from 20 years of preclinical testing in pediatric cancers

从20年的儿科癌症临床前测试中吸取的经验教训

2024-12-010
PRE
Phase I, two-part, multicenter first-in-human (FIH) study of TORL-1-23: A novel claudin 6 (CLDN6) targeting antibody drug conjugate (ADC) in patient with advanced solid tumors

I期,两阶段,多中心首次人体(FIH)研究:TORL-1-23——一种新型靶向Claudin 6(CLDN6)的抗体药物偶联物(ADC),用于晚期实体瘤患者。

2024-09-011
PRE
Tumor cell-specific bioluminescence platform to identify stroma-induced changes to anticancer drug activity (vol 16, pg 483, 2010)

肿瘤细胞特异性生物发光平台,用于鉴定基质诱导的抗癌药物活性变化 (第16卷,483页,2010页)

2024-02-140
OA